Gaspar E.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 48 partner sites.
Specializations
Hormone Receptor–Positive Breast Cancer
Focus on ER+/HER2- Early Breast Cancer and related endocrine strategies for patients after standard adjuvant therapy.
- Extended endocrine therapy
- Risk of early relapse
- Long‑term disease monitoring
Investigates therapeutic optimization for hormone‑driven disease.
Triple‑Negative Breast Cancer Immunotherapy
Evaluates the addition of atezolizumab to chemotherapy regimens for patients with triple‑negative breast cancer.
- Neoadjuvant checkpoint inhibition
- Event‑free survival improvement
- Adjuvant continuation strategies
Targets immune‑mediated control of high‑risk disease.
HER2‑Negative Breast Cancer Therapeutics
Addresses treatment options for HER2‑negative breast cancer patients with elevated relapse risk.
- Antibody‑drug conjugate evaluation
- Comparative effectiveness versus physician choice
- Invasive disease‑free survival endpoints
Seeks novel agents to reduce recurrence.
Metastatic Colorectal Cancer and Thromboembolic Prophylaxis
Studies prevention of venous thromboembolism using LMWH (tinzaparin) in patients with metastatic colorectal cancer initiating first‑line systemic therapy.
- Prophylactic anticoagulation impact
- Symptomatic VTE reduction
- Integration with chemotherapy or targeted agents
Combines oncologic and vascular risk management.
Minimal Residual Disease Monitoring via ctDNA
Implements ctDNA analysis to assess treatment efficacy and residual disease in early‑stage breast cancer.
- 90% ctDNA clearance as response marker
- Proof‑of‑concept therapeutic assessment
- Integration with endocrine and targeted regimens
Advances precision monitoring for curative intent.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.